JonesTrading analyst Soumit Roy reiterated a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $5.00. The company’s shares closed last Thursday at $1.01, close to its 52-week low of $0.90.
According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.4% and a 29.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $8.20, implying a 696.1% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
Aptose Biosciences’ market cap is currently $93.17M and has a P/E ratio of -1.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Read More on APTO:
- Why Did Designer Brands Stock Drop Despite 4x EPS Growth?
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mesoblast (MESO) and Immatics (IMTX)
- J.P. Morgan Sticks to Their Hold Rating for DoorDash (DASH)
- J.P. Morgan Thinks Phreesia’s Stock is Going to Recover
- Summit Materials (SUM) Receives a Buy from J.P. Morgan
